John­son & John­son is mak­ing an­oth­er ear­ly-stage on­col­o­gy deal, dish­ing out $1 bil­lion in cash to ac­quire Fire­fly Bio, a pre­clin­i­cal start­up work­ing on de­grad­er …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.